Scarica l'app Stockscreener
8.775
1.47%
-0.085
Precedente Chiudi:
$8.86
Aprire:
$8.81
Volume 24 ore:
137.96K
Relative Volume:
0.49
Capitalizzazione di mercato:
$586.04M
Reddito:
$555.06M
Utile/perdita netta:
$-39.48M
Rapporto P/E:
-14.63
EPS:
-0.6
Flusso di cassa netto:
$29.05M
1 W Prestazione:
+3.07%
1M Prestazione:
+8.04%
6M Prestazione:
+19.92%
1 anno Prestazione:
-19.17%
Intervallo 1D:
$8.63
$8.915
Intervallo di 1 settimana:
$8.11
$9.53
Portata 52W:
$5.81
$10.84
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS vs ABT, SYK, MDT, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
8.75 | 593.41M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
110.49 | 192.10B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
346.08 | 137.25B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
89.23 | 115.41B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.20 | 103.81B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
84.74 | 49.82B | 6.07B | 1.06B | 1.34B | 1.8063 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-09 | Iniziato | Barrington Research | Outperform |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges - Investing.com Nigeria
Bioventus Earnings Call Signals Profitable Growth Ahead - TipRanks
Bioventus Inc. (NASDAQ:BVS) Q4 2025 earnings call transcript - MSN
Momentum Shift: How is Bioventus Inc managing supply chain issues2026 Breakouts & Breakdowns & Stepwise Trade Signal Implementation - baoquankhu1.vn
Risks Report: Is Bioventus Inc exposed to currency risksJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - baoquankhu1.vn
Craig-Hallum Maintains Buy on Bioventus Inc (BVS) March 2026, PT $16 - Meyka
Aug Action: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Technical Pattern Alert System - baoquankhu1.vn
Bioventus (NYSE:BVS) In Focus as NYSE Composite Tracks MedTech Moves - Kalkine Media
Bioventus (BVS) Receives Updated Price Target from Barrington Re - GuruFocus
Bioventus (NYSE:BVS) Stock Price Expected to Rise, Barrington Research Analyst Says - MarketBeat
Bioventus (NASDAQ:BVS) Shares Down 8.2%Here's Why - MarketBeat
Bioventus (NYSE:BVS) Given New $16.00 Price Target at Craig Hallum - MarketBeat
Craig-Hallum raises Bioventus stock price target on guidance beat By Investing.com - Investing.com India
Craig-Hallum raises Bioventus stock price target on guidance beat - Investing.com South Africa
Bioventus Inc. (NASDAQ:BVS) Q4 2025 Earnings Call Transcript - Insider Monkey
Bioventus: Q4 Earnings Snapshot - theheraldreview.com
Bioventus earnings beat by $0.04, revenue topped estimates - Investing.com Australia
BVS Targets Revenue Range of $600M-$610M for FY26 - GuruFocus
Bioventus Q4 Earnings Call Highlights - MarketBeat
Bioventus Inc (BVS) Q4 2025 Earnings Call Highlights: Strong Org - GuruFocus
Bioventus (NYSE:BVS) Shares Gap UpHere's Why - MarketBeat
Bioventus Shares Rise After Analyst Upgrade - National Today
Bioventus Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Bioventus (NASDAQ:BVS) Shares Gap Up After Analyst Upgrade - MarketBeat
Bioventus (BVS) Q4 2025 Earnings Call Transcript - AOL.com
Earnings call transcript: Bioventus Inc. Q4 2025 beats EPS estimates, stock surges By Investing.com - Investing.com South Africa
Bioventus (NASDAQ:BVS) Rating Increased to Strong-Buy at Cantor Fitzgerald - MarketBeat
Bioventus shares jump 7.6% on fourth-quarter earnings beat By Investing.com - Investing.com Canada
Bioventus shares jump 7.6% on fourth-quarter earnings beat - Investing.com Australia
Bioventus beats Q4 estimates, guides 2026 revenue in line By Investing.com - Investing.com Australia
Bioventus Q4 2025 Earnings Call Transcript - MarketBeat
Bioventus 10-K: $568.1M Revenue, $0.33 Diluted EPS - TradingView
Bioventus (BVS) Exceeds Q4 Revenue Expectations, Eyes Future Gro - GuruFocus
Bioventus Q4 and Full Year 2025 Financial Results - TradingView
BIOVENTUS ($BVS) Releases Q4 2025 Earnings - Quiver Quantitative
Bioventus beats Q4 estimates, guides 2026 revenue in line - Investing.com India
Bioventus (NYSE:BVS) Updates FY 2026 Earnings Guidance - MarketBeat
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Bioventus Q4 Earnings Assessment - Benzinga
Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions - TradingView
Bioventus Earnings Report: Q4 Overview - Benzinga
BVS SEC FilingsBioventus Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Technical Analysis: Will Bioventus Inc benefit from rising consumer demandProduct Launch & Daily Oversold Bounce Ideas - baoquankhu1.vn
Preview: Bioventus's Earnings - Benzinga
Bioventus Inc. $BVS Shares Bought by Royce & Associates LP - MarketBeat
Bioventus (BVS) versus Its Peers Critical Comparison - Defense World
Bioventus (NYSE:BVS) Stock Price Down 0.1%Should You Sell? - MarketBeat
Bioventus Inc. (BVS) Stock Analysis: Unpacking A 63.66% Potential Upside - DirectorsTalk Interviews
Reviewing Bioventus (BVS) and Its Peers - Defense World
Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why - AOL.com
BVS | Bioventus Inc. Class A FinancialsIncome Statement - Quiver Quantitative
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.25%
1.00%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):